Home › Compound Library › GHRP-2 (Pralmorelin)

GHRP-2 (Pralmorelin)

Peptidesubcutaneous · inferred

Growth hormone releasing hexapeptide. More potent GH release than GHRP-6 with less hunger stimulation. Acts on ghrelin receptor (GHS-R1a). Half-life ~33 min. Typically dosed 100-300 mcg SC 2-3x/day. Often stacked with a GHRH (CJC-1295) for synergistic GH pulse.

Projected serum levels — 100 mcg (≈ 0.10 mg), twice daily

GHRP-2 (Pralmorelin)
GHRP-2 (Pralmorelin) modeled serum levels, 100 mcg (≈ 0.10 mg) twice daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1
GHRP-2 (Pralmorelin) modeled serum levels with a loading dose of 153 mcg, then 100 mcg (≈ 0.10 mg) twice daily The first dose is larger so levels approach steady state faster. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 100 mcg (≈ 0.10 mg) twice daily (subcutaneous).

Loading schedule: 153 mcg on day 1, then 100 mcg (≈ 0.10 mg) twice daily — reaching therapeutic levels sooner.

Modeled steady state after ~1 days: peak ≈ 0.068 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Peptide
Route modeled
Subcutaneous
Model confidence
inferred
Half-life
33 min
Common dose
100 mcg (≈ 0.10 mg)
Suggested maximum
300 mcg/day
Reference dose range
50–300 mcg (single dose)
Suggested cadence
twice daily

Documented interactions

  • caution
    GHRP-6 + GHRP-2 (Pralmorelin) Potentiation

    Both are ghrelin receptor agonists. Stacking two GHRPs provides diminishing returns as they compete for the same receptor.

  • caution
    Ipamorelin + GHRP-2 (Pralmorelin) Potentiation

    Both are GH secretagogues acting on similar pathways. Stacking provides diminishing returns.

  • watch
    BPC-157 (Body Protection Compound) + GHRP-2 (Pralmorelin) Stacked effects

    BPC-157 (Body Protection Compound) and GHRP-2 (Pralmorelin) both push the growth hormone receptor in the same direction.

  • watch
    HGH (Human Growth Hormone / Somatropin) + GHRP-2 (Pralmorelin) Stacked effects

    GHRP-2 (Pralmorelin) and HGH (Human Growth Hormone / Somatropin) both push the growth hormone receptor in the same direction.

  • watch
    Ibutamoren (MK-677) + GHRP-2 (Pralmorelin) Stacked effects

    GHRP-2 (Pralmorelin) and Ibutamoren (MK-677) both push the ghrelin receptor in the same direction.

Serum checks 7 modeled interaction pairings for ghrp-2 (pralmorelin) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Pharmacokinetics and Pharmacodynamics of Growth Hormone-Releasing Peptide-2: A Phase I Study in Children Pihoker C et al. · Journal of Clinical Endocrinology & Metabolism, 1998 DOI

    Phase I PK/PD study showing GHRP-2 half-life of 33 min with dose-dependent GH release peaking at 15-30 min post-injection in children.

  2. Growth Hormone Releasing Peptides: A Comparison of the Growth Hormone Releasing Activities of GHRP-2 and GHRP-6 Bowers CY et al. · Journal of Endocrinological Investigation, 1997 DOI

    Comparative study showing GHRP-2 produces greater GH release than GHRP-6 in rat pituitary cells, with higher receptor binding affinity.

  3. Growth Hormone Secretagogues: History, Mechanism of Action, and Clinical Development Ishida J et al. · JCSM Rapid Communications, 2020 DOI

    Comprehensive review of GH secretagogue development from GHRP-6 through GHRP-2 to non-peptide mimetics, covering mechanism, PK, and clinical applications.

3 published studies referenced in the app, each with a plain-language summary.